Skip to main content
Article
Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naive, first-episode schizophrenia
Psychiatry Publications and Presentations
  • Xueqin Song, Zhengzhou University
  • Xiaoduo Fan, University of Massachusetts Medical School
  • Xue Li, Zhengzhou University
  • Wei Zhang, Zhengzhou University
  • Jinsong Gao, Zhengzhou University
  • Jingping Zhao, Central South University
  • Amy Harrington, University of Massachusetts Medical School Worcester
  • Douglas M. Ziedonis, University of Massachusetts Medical School
  • Luxian Lv, Xinxiang Medical University
UMMS Affiliation
Department of Psychiatry
Date
1-1-2014
Document Type
Article
Abstract

OBJECTIVE: The present study aimed to examine the changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naive, first-episode schizophrenia.

METHODS: Sixty-two drug naive, first-episode schizophrenia (SZ group) and 60 healthy individuals (control group) were enrolled in the study. Serum interleukin-1beta (IL-1beta), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) levels, and body weight were measured at baseline for both groups, and repeated for the SZ group at five different time points during 6-month risperidone treatment.

RESULTS: At baseline, serum IL-1beta, IL-6, and TNF-alpha levels in the SZ group (53.28 +/- 12.62, 33.98 +/- 14.13, 50.08 +/- 12.86 pg/mL, respectively) were significantly higher than those in the control group (23.49 +/- 15.27, 15.53 +/- 7.16, 32.12 +/- 15.23 pg/mL, respectively) (p's < 0.001). Within the SZ group, serum IL-1beta levels decreased significantly at 2 weeks (48.02 +/- 16.00 pg/mL, p < 0.01) and 1 month (44.70 +/- 16.63 pg/mL, p < 0.001), but then gradually increased at 2 months (48.49 +/- 18.87 pg/mL), 3 months (50.59 +/- 18.48 pg/mL) and 6 months (53.64 +/- 16.22 pg/mL) to the levels comparable to baseline; serum IL-6 levels changed significantly over the course of treatment (p = 0.001), but reached the levels comparable to baseline at 6 months (37.13 +/- 13.23 pg/mL); serum levels of TNF-alpha increased significantly at 3 months (55.02 +/- 16.69 pg/mL, p < 0.01) and 6 months (58.69 +/- 13.57 pg/mL, p < 0.001); steady and significant weight gain was observed at each follow-up time point (p's < 0.001), from 56.71 +/- 9.25 kg at baseline to 62.72 +/- 9.53 kg at 6 months.

CONCLUSIONS: Risperidone treatment is associated with changes in serum pro-inflammatory cytokines levels and weight. There is an initial anti-inflammatory effect that reduces with treatment, potentially due to its weight gain side effect.

Rights and Permissions
Citation: Psychopharmacology (Berl). 2014 Jan;231(2):319-25. doi: 10.1007/s00213-013-3382-4Link to article on publisher's site
Related Resources
Link to Article in PubMed
PubMed ID
24337064
Citation Information
Xueqin Song, Xiaoduo Fan, Xue Li, Wei Zhang, et al.. "Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naive, first-episode schizophrenia" Vol. 231 Iss. 2 (2014) ISSN: 0033-3158 (Linking)
Available at: http://works.bepress.com/douglas_ziedonis/126/